NASDAQ:KYMR

Kymera Therapeutics News Headlines

$33.44
-1.55 (-4.43 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$32.88
Now: $33.44▼
$34.61
50-Day Range
$34.99
MA: $46.84▼
$60.04
52-Week Range
$25.43
Now: $33.44▼
$91.92
Volume249,824 shs
Average Volume313,598 shs
Market Capitalization$1.50 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Kymera Therapeutics (NASDAQ KYMR) News Headlines Today

SourceHeadline
Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021
finance.yahoo.com - April 10 at 8:55 AM
Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 5.5%Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 5.5%
americanbankingnews.com - April 9 at 2:38 PM
Kymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology (SID) 2021 Annual MeetingKymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology (SID) 2021 Annual Meeting
finance.yahoo.com - April 9 at 12:18 PM
Kymera Therapeutics (NASDAQ:KYMR) Sees Strong Trading VolumeKymera Therapeutics (NASDAQ:KYMR) Sees Strong Trading Volume
americanbankingnews.com - March 31 at 12:56 PM
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by AnalystsKymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by Analysts
americanbankingnews.com - March 25 at 5:32 PM
Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 6.4%Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 6.4%
americanbankingnews.com - March 25 at 11:37 AM
Kymera Therapeutics Becomes Oversold (KYMR)Kymera Therapeutics Becomes Oversold (KYMR)
nasdaq.com - March 24 at 1:01 PM
Kymera Therapeutics (NASDAQ:KYMR) Price Target Cut to $69.00Kymera Therapeutics (NASDAQ:KYMR) Price Target Cut to $69.00
americanbankingnews.com - March 23 at 11:08 AM
Kymera Therapeutics (NASDAQ:KYMR) Trading 6.2% Higher Kymera Therapeutics (NASDAQ:KYMR) Trading 6.2% Higher
americanbankingnews.com - March 22 at 2:42 PM
Kymera Therapeutics (NASDAQ:KYMR) Shares Down 13.9% Kymera Therapeutics (NASDAQ:KYMR) Shares Down 13.9%
americanbankingnews.com - March 18 at 9:14 PM
Bruce Booth Sells 229,350 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) StockBruce Booth Sells 229,350 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock
americanbankingnews.com - March 16 at 10:48 PM
Kymera Therapeutics Appoints Elena Ridloff, CFA, to Board of DirectorsKymera Therapeutics Appoints Elena Ridloff, CFA, to Board of Directors
finance.yahoo.com - March 16 at 6:52 PM
Kymera Therapeutics Inc (KYMR) CFO Bruce N. Jacobs Sold $601,500 of SharesKymera Therapeutics Inc (KYMR) CFO Bruce N. Jacobs Sold $601,500 of Shares
finance.yahoo.com - March 16 at 12:51 AM
Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business UpdateKymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update
finance.yahoo.com - March 11 at 7:42 AM
Kymera Therapeutics Inc (KYMR) CFO Bruce N. Jacobs Sold $506,500 of SharesKymera Therapeutics Inc (KYMR) CFO Bruce N. Jacobs Sold $506,500 of Shares
finance.yahoo.com - March 9 at 1:36 AM
Kymera Therapeutics Inc (KYMR) CFO Bruce N. Jacobs Sold $895,600 of SharesKymera Therapeutics Inc (KYMR) CFO Bruce N. Jacobs Sold $895,600 of Shares
finance.yahoo.com - March 5 at 8:48 PM
Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory DiseasesKymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases
finance.yahoo.com - March 2 at 8:10 AM
Kymera Therapeutics to Present at Upcoming March Investor ConferencesKymera Therapeutics to Present at Upcoming March Investor Conferences
finance.yahoo.com - February 25 at 8:34 AM
Kymera Therapeutics, Inc. (KYMR)Kymera Therapeutics, Inc. (KYMR)
realmoney.thestreet.com - February 8 at 12:50 AM
KYMR Crosses Above Average Analyst TargetKYMR Crosses Above Average Analyst Target
nasdaq.com - February 4 at 8:46 AM
Kymera Therapeutics Strengthens Leadership with Key Appointments and PromotionsKymera Therapeutics Strengthens Leadership with Key Appointments and Promotions
finance.yahoo.com - February 3 at 9:20 AM
Kymera Therapeutics Is A Protein Degrading Pioneer With A Triple-Figure Share Price In WaitingKymera Therapeutics Is A Protein Degrading Pioneer With A Triple-Figure Share Price In Waiting
seekingalpha.com - January 16 at 7:58 AM
Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines CompanyKymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company
finance.yahoo.com - January 12 at 11:24 AM
Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021
finance.yahoo.com - January 5 at 6:07 PM
Vertex (VRTX) Inks Deal with Skyhawk for Serious DiseasesVertex (VRTX) Inks Deal with Skyhawk for Serious Diseases
msn.com - December 23 at 12:33 PM
Is KYMR A Good Stock To Buy Now According To Hedge Funds?Is KYMR A Good Stock To Buy Now According To Hedge Funds?
finance.yahoo.com - December 19 at 8:06 PM
Kymera Therapeutics Announces Key Leadership AppointmentsKymera Therapeutics Announces Key Leadership Appointments
finance.yahoo.com - December 16 at 8:43 AM
Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd American Society of Hematology (ASH) Annual MeetingKymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - December 7 at 3:59 PM
Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This WeekAnalysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week
finance.yahoo.com - November 26 at 8:03 AM
Kymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare ConferenceKymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare Conference
finance.yahoo.com - November 23 at 8:39 AM
Kymera Therapeutics to Present at the Stifel 2020 Virtual Healthcare ConferenceKymera Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
finance.yahoo.com - November 11 at 1:03 PM
Kymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business UpdateKymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - November 5 at 11:08 AM
Kymeras protein degradation programs show encouraging preclinical action in cancerKymera's protein degradation programs show encouraging preclinical action in cancer
seekingalpha.com - November 4 at 12:41 PM
Kymera Therapeutics to Present Data on Novel IRAKIMiD and STAT3 Protein Degraders at Virtual 62nd American Society of Hematology (ASH) Annual MeetingKymera Therapeutics to Present Data on Novel IRAKIMiD and STAT3 Protein Degraders at Virtual 62nd American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 4 at 12:41 PM
Kymera Reports Positive Data, And Other News: The Good, Bad And Ugly Of BiopharmaKymera Reports Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - October 13 at 1:35 PM
Kymera Therapeutics Rings the Opening Bell in Celebration of its IPOKymera Therapeutics Rings the Opening Bell in Celebration of its IPO
nasdaq.com - October 12 at 3:17 PM
Kymera Therapeutics Announces Pricing of Upsized Initial Public OfferingKymera Therapeutics Announces Pricing of Upsized Initial Public Offering
finance.yahoo.com - October 1 at 8:31 AM
Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and Concurrent Private PlacementKymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
finance.yahoo.com - October 1 at 8:31 AM
Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific OfficerKymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer
finance.yahoo.com - October 1 at 8:31 AM
This page was last updated on 4/10/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.